< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

2 clusters · 7 sources · 1 days · First seen 7 days ago · Last updated 6 days ago

Categories: HEALTH

Revel Pharmaceuticals AGE‑reversal enzyme

Entities: CMLase · CMLase enzyme · advanced glycation end‑products · Revel Pharmaceuticals · Aaron Cravens

Overview

In late July 2026, researchers at Revel Pharmaceuticals announced the creation of an enzyme capable of breaking down advanced glycation end‑products (AGEs), molecular markers of age‑related tissue damage. An initial report highlighted the enzyme’s ability to chemically reverse carboxymethyl‑lysine in laboratory models, reducing collagen stiffness and improving cellular function, while noting that the work was still at an early, pre‑clinical stage.

Follow‑up reports clarified that the enzyme, named CMLase, was discovered through AI analysis of thousands of microbial DNA sequences and further optimised by directed‑evolution techniques. Tests on donated human skin and artery tissue from donors in their 70s showed that CMLase could lower AGE levels to those typical of individuals in their early 30s, providing a stronger proof‑of‑concept that molecular damage from ageing might be mitigated. The findings were published in Nature Communications (July 16) and presented by Revel founder‑CEO Aaron Cravens, who stressed that the results demonstrate structural reversal of CML but remain far from clinical application. Both reports continue to stress the need for extensive further research before any therapeutic use can be pursued.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 2 SOURCES] A laboratory‑designed enzyme called CMLase eliminates advanced glycation end‑products (AGEs) in human tissue samples. (Aaron Cravens, Revel Pharmaceuticals)
[● 2 SOURCES] The study describing CMLase was published on 16 July in the journal Nature Communications. (Study authors)
[○ 1 SOURCE] The enzyme CMLase was developed using AI analysis of over 50,000 microbial DNA sequences and directed‑evolution optimisation. (Research team at Revel Pharmaceuticals)
[○ 1 SOURCE] In tests, skin from a 70‑year‑old donor treated with CMLase showed AGE levels comparable to those of a 30‑year‑old. (Aaron Cravens, Revel Pharmaceuticals)
[○ 1 SOURCE] Aaron Cravens is a founder and CEO of Revel Pharmaceuticals and the lead author of the enzyme study. (Study authors)

Timeline

6 days ago

[HEALTH] 4 sources
Revel Pharmaceuticals unveils enzyme that cuts age‑related tissue compounds
Scientists at Revel Pharmaceuticals created enzyme CMLase that degrades advanced glycation end‑products, lowering AGE levels in aged skin to those of a younger adult; results published July 16 in Nature Commun
7 days ago

[HEALTH] 3 sources
New Enzyme Shows Promise in Reversing Age‑Related Protein Damage
Scientists engineered an enzyme that reverses protein AGE damage, offering early proof‑of‑concept for restoring tissue function and potentially slowing age‑related diseases.

Sources

ibtimes.com · indyturk.com · karar.com · m.n.com.do · startuppakistan.com.pk · vanguardia.com.mx · world-today-journal.com